dr. salgia on crizotinib and other tkis in alk-positive nsclc
Published 6 years ago • 255 plays • Length 1:11Download video MP4
Download video MP3
Similar videos
-
1:59
dr. ravi salgia on crizotinib-resistant patients
-
1:22
dr. crinò on crizotinib in alk nsclc
-
0:44
dr. mark kris discusses crizotinib for patients with alk-positive lung cancer
-
4:10
crizotinib resistance in alk nsclc
-
1:38
dr. ravi salgia on eml4-alk in a cancer cell
-
6:04
case study: progression on alk inhibitors in nsclc
-
8:25
alk-positive lung cancer
-
13:28
debate: alk positive nsclc - front line therapy - crizotinib
-
1:17
dr. christina baik on alectinib versus crizotinib in alk-positive lung cancer
-
1:52
dr. shaw on crizotinib versus chemotherapy in alk-positive nsclc
-
7:02
crizotinib for alk-rearranged nsclc
-
8:24
second-line treatment for alk-positive nsclc
-
3:34
alk-positive nsclc: the role of treatment selection and sequencing
-
1:58
dr. shaw on crizotinib in alk-positive lung cancer
-
8:51
alk-positive nsclc
-
1:09
dr. camidge on crizotinib as a ros1 inhibitor in nsclc
-
1:21
dr. shaw on crizotinib resistance in alk-positive lung cancer
-
1:42
dr. alice shaw compares crizotinib and chemotherapy in nsclc
-
4:38
patterns of progression on crizotinib for alk nsclc